Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
The five-membered hetero ring consists of one nitrogen and four carbons
Subclass of:
514 - Drug, bio-affecting and body treating compositions
514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)
514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI
514359000 - Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)
Patent class list (only not empty are listed)
Deeper subclasses:
| Class / Patent application number | Description | Number of patent applications / Date published |
|---|---|---|
| 514410000 | Polycyclo ring system having the five-membered hetero ring as one of the cyclos | 564 |
| 514423000 | C=X bonded directly to the five-membered hetero ring by nonionic bonding (X is chalcogen) | 144 |
| 514424000 | Chalcogen bonded directly to the five-membered hetero ring by nonionic bonding | 74 |
| 514422000 | Additional hetero ring | 64 |
| 514409000 | Spiro ring system | 34 |
| 514428000 | Chalcogen bonded indirectly to the five-membered hetero ring by acyclic nonionic bonding | 27 |
| 514427000 | Two double bonds between ring members of the five-membered hetero ring (e.g., pyrrole, etc.) | 14 |
| 514426000 | Nitrogen bonded directly to the five-membered hetero ring by nonionic bonding | 11 |
| 514429000 | Carbocyclic ring bonded directly to the five-membered hetero ring | 2 |
| 20090306175 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR - The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT | 12-10-2009 |
| 20100197760 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION - The present invention provides compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-(disubstituted aryl)-pyrrolidines for the treatment of central nervous system disorders. | 08-05-2010 |
| Entries | ||
| Document | Title | Date |
|---|---|---|
| 20100105753 | Inhibitors of Fibroblast Activation Protein, and Methods of Use Thereof - One aspect of the present invention relates to synthetic peptide derivatives that inhibit fibroblast activation protein α (FAP) activity. Another aspect of the invention relates to methods for treating a mammal suffering from cancer by administering a therapeutically effective amount of synthetic peptides derivatives that inhibit FAP activity. | 04-29-2010 |
| 20090012144 | Optically active 2,5-bisaryl-delta¹ -pyrrolines and their use as pest control agents - Novel optically active Δ | 01-08-2009 |
| 20090062366 | Pyrrolidine derivative or salt thereof - [Problem] To provide a compound which may be used in treating diseases in which a calcium sensing receptor (CaSR) is concerned, particularly hyperparathyroidism. | 03-05-2009 |
| 20090076114 | Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes - The present invention relates to cis-1,2-substituted stilbene derivatives, or their pharmaceutically acceptable salts, glucosides or solvates, a pharmaceutical composition comprising the compound, and use of said compound for preparation of a drug for treatment and/or prevention of diabetes or improvement of diabetic complications. | 03-19-2009 |
| 20100292288 | CRYSTALLINE FORMS OF (R)-1-{2-[4`- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO - The present invention is directed to novel salts of (R)-1-{2-[4′-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and crystalline forms, and compositions thereof that modulate the activity of the histamine H3-receptor and are useful in the treatment of histamine H3-receptor associated disorders, such as, cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness such as narcolepsy, shift-work syndrome, drowsiness as a side effect from a medication, maintenance of vigilance to aid in completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, pain, dementia, Alzheimer's disease and the like. | 11-18-2010 |
| 20100204294 | Methods For Assessing, Improving, Or Maintaining Urogenital Health in Postmenopausal Woman - This invention relates to methods and kits useful for improving or maintaining urogenital health using an estrogen agonist/antagonist. The methods of treatment are effective for improving or maintaining urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. This invention also relates to methods of assessing vaginal health. | 08-12-2010 |